Vivoryon Therapeutics Management
Management criteria checks 2/4
Vivoryon Therapeutics' CEO is Frank Weber, appointed in Aug 2023, has a tenure of 1.33 years. total yearly compensation is €528.32K, comprised of 16.3% salary and 83.7% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth €67.70K. The average tenure of the management team and the board of directors is 6.2 years and 1.9 years respectively.
Key information
Frank Weber
Chief executive officer
€528.3k
Total compensation
| CEO salary percentage | 16.3% |
| CEO tenure | 1.3yrs |
| CEO ownership | 0.1% |
| Management average tenure | 6.2yrs |
| Board average tenure | 1.9yrs |
Recent management updates
Recent updates
We Think Vivoryon Therapeutics (AMS:VVY) Needs To Drive Business Growth Carefully
Dec 05
Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 28Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
May 04Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 02Here's Why We're Not Too Worried About Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
Jan 26Companies Like Vivoryon Therapeutics (AMS:VVY) Are In A Position To Invest In Growth
Sep 16We Think Vivoryon Therapeutics (AMS:VVY) Can Afford To Drive Business Growth
May 10Is Vivoryon Therapeutics N.V.'s (AMS:VVY) Shareholder Ownership Skewed Towards Insiders?
Mar 11We're Hopeful That Vivoryon Therapeutics (AMS:VVY) Will Use Its Cash Wisely
Jan 14
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€31m |
| Mar 31 2024 | n/a | n/a | -€30m |
| Dec 31 2023 | €528k | €86k | -€28m |
Compensation vs Market: Frank's total compensation ($USD555.37K) is about average for companies of similar size in the Dutch market ($USD480.27K).
Compensation vs Earnings: Insufficient data to compare Frank's compensation with company performance.
CEO
Frank Weber (64 yo)
1.3yrs
Tenure
€528,320
Compensation
Dr. Frank T. Weber M. D. has been Chief Medical and Development Officer (CMDO) of Vivoryon Vivoryon Therapeutics N. V. (formerly known as Vivoryon Therapeutics AG & Probiodrug AG) since September 1, 2019....
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Management Board | 1.3yrs | €528.32k | 0.13% € 64.5k | |
| CSO & Investor Relations Officer | 1.3yrs | €405.12k | no data | |
| Chief Business Officer | 6.2yrs | €923.00k | no data | |
| Director of Investor Relations & Communications | no data | no data | no data | |
| Co-Founder & Advisor | no data | €222.11k | no data | |
| Advisor | no data | €319.20k | no data |
6.2yrs
Average Tenure
55yo
Average Age
Experienced Management: VVY's management team is seasoned and experienced (6.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Management Board | 1.3yrs | €528.32k | 0.13% € 64.5k | |
| CSO & Investor Relations Officer | 1.3yrs | €405.12k | no data | |
| Chief Business Officer | no data | €923.00k | no data | |
| Independent Non-Executive Chairman | no data | €246.00k | 1.36% € 675.3k | |
| Independent Non-Executive Director | no data | €236.00k | no data | |
| Independent Non-Executive Director | 2.5yrs | €337.00k | no data | |
| Independent Non-Executive Director | 2.5yrs | €224.00k | 0.0038% € 1.9k |
1.9yrs
Average Tenure
55yo
Average Age
Experienced Board: VVY's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.